As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...

Objective: To assess health care practitioners' ability to correctly measure the QT interval, and to identify factors and medications that may increase the risk of QT-interval prolongation and ...

February 4, 2010 (Washington, DC) — A profoundly simple test that takes advantage of the brief heart-rate acceleration that occurs when one stands up, especially if it's done quickly, could ...

AliveCor is also offering a service called InstantQT™ to assist in measuring QT intervals through an FDA-cleared, ECG processing software. The Food and Drug Administration (FDA) has cleared the ...

This section describes the evidence gaps, why they need to be addressed and their relative importance for future committee decision making. The committee will not be able to make a positive ...

AliveCor's at-home EKG device won FDA clearance to calculate a heart's QT interval, a measurement of how long it takes the ventricles to contract and relax. This is vital given that some drugs can ...

ADInstruments has announced that PowerLab systems are being used to establish the zebrafish as a model for assessing drug effects on cardiac function, using QT prolongation as a key indicator.

Until recently, cardiac toxicity manifesting in the form of arrhythmias related to QT interval prolongation was uncommonly appreciated within the antimicrobial class of drugs, but it was well ...